Madrigal Pharmaceuticals (MDGL) Change in Receivables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 5 years of Change in Receivables data on file, last reported at $52.9 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 595.24% year-over-year to $52.9 million in Q1 2026; TTM through Mar 2026 was $125.9 million, a 105.0% increase from a year earlier, with the FY2025 full-year figure at $80.7 million, up 49.85% from the prior year.
• Change in Receivables for Q1 2026 stood at $52.9 million, up from $21.2 million in the prior quarter.
• Over the last five years, Change in Receivables for MDGL reached as high as $52.9 million in Q1 2026 and fell as low as $6.9 million in Q2 2024.
• Historically, Change in Receivables has averaged $23.4 million across 3 years, with a median of $22.3 million in 2024.
• Across the five-year window, Change in Receivables fell 9.28% in 2025 and soared 595.24% in 2026, its largest moves.
• Year by year, Change in Receivables stood at $23.4 million in 2024, then retreated by 9.28% to $21.2 million in 2025, then surged by 149.54% to $52.9 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $52.9 million in Q1 2026, $21.2 million in Q4 2025, and $34.1 million in Q3 2025.